Spikeopathy, in one paragraph
Spikeopathy refers to chronic sequelae mechanistically linked to persistent SARS-CoV-2 spike protein — from infection or mRNA vaccination. Core features: neuroinflammation, protein misfolding, mitochondrial dysfunction, endothelial damage, microclots, and symptoms like brain fog, fatigue, autonomic dysfunction. The term is mechanistic, not a clinical diagnosis. It is not in ICD-10/11, NICE, or WHO classifications. Read this cluster as a structured exploration of a hypothesis, not a diagnostic manual.
The guiding framework
The detailed articles below describe specific mechanisms — mTOR, glymphatic flow, SIRT1, mast cells, microclots, DNA-driven cGAS-STING. Each is a node. This is the network they sit in, and without it the nodes look like a list of unrelated problems. They are not.
The model [HYPOTHESIS — convergent inference from mechanism work; testable; not yet validated as a clinical framework]:
Spike-related chronic illness is best understood as systemic clearance and tolerance failure under persistent antigenic drive. Spike protein, or its fragments, persists in tissue reservoirs [AUTOPSY], creating ongoing immune stimulation. That stimulation overwhelms or dysregulates the body's clearance systems — autophagy inside cells, glymphatic and immune clearance outside them — and corrupts the tolerance checkpoints that decide whether a loaded cell should be attacked or ignored [MECHANISTIC + HUMAN-IMAGING]. The downstream consequences are what present as symptoms: misfolded proteins and damaged mitochondria accumulate, inflammation becomes chronic rather than resolving, barriers leak, and neuroimmune loops self-reinforce [HUMAN-IMAGING + MECHANISTIC].
Every mechanism this cluster documents is an instance of one of three things: the drive persists, the clearance fails, or the tolerance decision goes wrong. They are not separate diseases. They are three failure modes of one system.
How the loop runs:
- Drive persists — spike/fragments in tissue reservoirs keep the immune system activated; microclots shelter seeded protein from clearance
- Clearance fails — autophagy (inside cells) and glymphatic flow (between cells) can't keep up; the plumbing clogs; waste backs up
- Tolerance corrupts — RAGE/IL-10 keeps spike-loaded cells alive that should be cleared; EPO–EPOR disrupts oxygen delivery; mast-cell–microglia loops inflame the meninges
- Consequences compound — waste accumulates, inflammation chronifies, mitochondria exhaust, barriers leak
- Symptoms emerge — brain fog, fatigue, post-exertional malaise, dysautonomia, microclot signs
- Loop amplifies — symptoms worsen sleep and lower exertion tolerance, which further impairs clearance, back to the top
The intervention principle. Because the failure is systemic, the highest-leverage response is systemic, not pathway-by-pathway: clean the system and support regeneration. The detailed mechanisms are useful for identifying the dominant node in an individual — the place where intervention buys the most. They are tactical levers underneath one functional model. The full lever map is in the next section.
How this cluster is organised
Four articles, organised by question. Start at the top if you're new. Skip to the protocol if you just want the levers.
| Question | Read this | What it covers |
|---|---|---|
| What clearance systems fail, and why? | Pathways: mTOR, Glymphatic, SIRT1/PGC-1α | The flagship. Dual-mTOR model, glymphatic failure, 2025 DTI-ALPS imaging, compound matrix, falsifiability section |
| Which subtype are you? | Stratification: Five Mechanistic Subtypes | 5-subtype framework, orderable biomarker matrix with UK tiers, per-subtype compound shortlists, honest gaps |
| Why won't spike clear? | Spike Persistence: Microclots, Reactivated Viruses | Tissue reservoirs, mTOR/p53 survival mechanism, RAGE/IL-10 tolerance trap, TMEM106B, APOE4/BBB, biomarker panel |
| What compounds work? | Spike Protocol: Evidence Snapshot | Nattokinase, NAC, curcumin, quercetin, lions mane, oregano. Evidence tiers, dosing cautions, lab monitoring |
Systemic & regenerative levers
The north-star layer. Five functional buckets. Each names the goal and the lever class; specifics (compounds, dosing, cautions, monitoring) live in the linked articles. The point here is the shape of the response, not a shopping list.
1. Reduce the antigenic load. Clear the reservoirs and the resistant waste so the clearance systems stop being permanently overwhelmed. Lever classes: fibrinolytics (nattokinase, lumbrokinase) for microclot/amyloid-fibrin clearance; persistence-targeting strategies (mTOR modulation, antiviral support); plasmapheresis where appropriate. This is the bucket most likely to involve prescription agents and clinician oversight — do not self-prescribe, especially on anticoagulants. → Spike Persistence, Spike Protocol, Amyloid Fibrin
2. Restore clearance capacity. Get the two waste-removal systems working again. Lever classes: sleep optimisation (the glymphatic system runs in deep sleep — this is non-negotiable, not a nice-to-have); time-restricted eating to trigger autophagy; daily movement to drive the glymphatic pump via arterial pulsation; PBM/NIR. → Pathways: mTOR, Glymphatic, SIRT1
3. Resolve inflammation and restore tolerance. Break the loops that keep the system stuck in chronic inflammation, and fix the tolerance decisions that let loaded cells survive. Lever classes: Nrf2 activators (sulforaphane); cGAS-STING dampeners (baicalin); mast-cell stabilisers (luteolin, quercetin, ketotifen, LDN) for the neuroimmune arm; awareness of the RAGE/IL-10 tolerance trap when interpreting why some interventions underperform. → Pathways, Stratification — mast-cell subtype
4. Support regeneration. Rebuild the energy supply both clearance systems depend on, and the repair capacity the body needs to recover from accumulated damage. Lever classes: NAD⁺ precursors (NR, NMN) and the SIRT1/PGC-1α axis; ubiquinol; mitochondrial biogenesis support; nutrition. This bucket is primary (not adjunctive) for the mitochondrial-dominant subtype. → Pathways — SIRT1/PGC-1α, Stratification — mitochondrial subtype
5. Monitor and titrate. This site treats measurement as a first-class lever, not an afterthought. Blanket protocols fail because the dominant node differs between people. Track within-person trends on biomarkers (D-dimer, fibrinogen, hs-CRP, ferritin, NfL, GFAP, HOMA-IR, lactate, tryptase) alongside symptom logs. Iteration beats dogma. → Stratification — biomarker matrix, Spike Persistence — biomarker panel
Sequence matters. If clearance is blocked (microclots, severe sleep failure), regeneration support alone won't reach the tissue. If tolerance is corrupted, clearance alone recovers the same cell that re-accumulates waste. Most people need all five buckets — but the order and the dominant node are individual. That's what the stratification work is for.
Start with this
If you only read one piece, read Pathways: mTOR, Glymphatic, and SIRT1/PGC-1α. It is the pathway-mechanics layer the others build on. Plain English up front, levers next, mechanism and evidence after, falsifiability at the end. Not defended — revised or abandoned if the predictions fail.
Adjacent articles in the cluster
- Amyloid Fibrin & Mass Casualty Misdiagnosis — amyloid pathology, forensic findings, diagnostic gap
- Intranasal Vaccine Risk: BPL-1357 — olfactory retrograde transport, Taubenberger/NIAID continuity
- The Case for Halting mRNA Experiments — interaction matrix, DNA contamination forensics
- Insertional Mutagenesis Defense — genomic integrity, natural compound defense layers
- HIV Protein Mimicry — molecular mimicry, TAT parallels
How the work is graded
Every claim in the cluster carries an evidence tag — [ESTABLISHED], [HUMAN-IMAGING], [AUTOPSY], [MECHANISTIC], [HYPOTHESIS]. Weigh each claim on its own. Don't bundle them. Full grading system, sourcing standard, and correction policy on the Methodology page.
What this cluster does not do
- It does not claim any intervention reverses spikeopathy.
- It does not cover lab origin, DNA contamination forensics, or oncogenic p53/RAGE pathways in depth. Those live in genomic-defense, DNA-Contamination, and hiv-protein-mimicry respectively.
- It is not a substitute for clinical care. If you are managing post-COVID or post-vaccine illness, work with a clinician who knows the literature.
Errors of interpretation are mine. Corrections welcome.